ストックスクリーナーアプリを入手
3.40
1.19%
0.04
Vaccinex Inc (VCNX) 最新ニュース
VSME’s price-to-free cash flow ratio: What it means for investors - US Post News
Vaccinex stock hits 52-week low at $4.17 amid sharp annual decline - Investing.com
Short Interest in Victory Square Technologies Inc. (OTCMKTS:VSQTF) Declines By 79.4% - Defense World
Vaccinex stock hits 52-week low at $4.17 amid sharp annual decline - Investing.com UK
Viemed Healthcare, Inc. (NASDAQ:VMD) Shares Purchased by Victory Capital Management Inc. - Defense World
WUXI BIO Buys back ~3.32M Shrs for ~$42.55M Ytd - AASTOCKS.com
Vaxcyte Inc (PCVX) receives a Buy rating from Mizuho - Knox Daily
Victrex plc (LON:VCT) Insider Jane Toogood Acquires 508 Shares - MarketBeat
Victrex Director Buys Shares, Signals Confidence - TipRanks
Bank of New York Mellon Corp Boosts Stock Holdings in Viemed Healthcare, Inc. (NASDAQ:VMD) - Defense World
StockNews.com Initiates Coverage on Vector Group (NYSE:VGR) - Defense World
VICR Investors Have Opportunity to Lead Vicor Corporation Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
The Gross Law Firm Reminds Vicor Corporation Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 23, 2024VICR - PR Newswire
Victory Capital Management Inc. Has $496,000 Stock Holdings in Zymeworks Inc. (NYSE:ZYME) - Defense World
Rhumbline Advisers Has $1.01 Million Position in V2X, Inc. (NYSE:VVX) - Defense World
Choreo LLC Takes Position in Vector Group Ltd. (NYSE:VGR) - Defense World
VICOR 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Vicor CorporationVICR - Business Wire
VICR FINAL DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, - GlobeNewswire
First Eagle Investment Management LLC Purchases 2,067 Shares of V2X, Inc. (NYSE:VVX) - Defense World
Vaccinex issues new warrants, secures $6.2 million in funding - Investing.com
Vaccinex issues new warrants, secures $6.2 million in funding - Investing.com India
Victory Capital Management Inc. Cuts Stake in Wyndham Hotels & Resorts, Inc. (NYSE:WH) - Defense World
Vaccinex secures $6.2 million through warrant exercises By Investing.com - Investing.com Canada
What's Going On With Vaccinex Stock Wednesday? - Benzinga
Vaccinex secures $6.2 million through warrant exercises - Investing.com India
Vaccinex secures $6.2 million through warrant exercises By Investing.com - Investing.com Australia
Vaccinex secures $6.2 million through warrant exercises - Investing.com
Vaccinex secures $6.2 million through warrant exercises By Investing.com - Investing.com UK
Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds - GlobeNewswire
Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds - StockTitan
(VCNX) Investment Report - Stock Traders Daily
Vaccinex, Inc. (NASDAQ:VCNX) Sees Large Decline in Short Interest - Defense World
Vaccinex Director Chrystyna Bedrij Stecyk Abruptly Resigns - TipRanks
Vaccinex announces warrant cancellation option - Investing.com India
Vaccinex announces warrant cancellation option By Investing.com - Investing.com Canada
Vaccinex announces warrant cancellation option By Investing.com - Investing.com UK
Vaccinex (VCNX) Extends Rally With New Clinical Insights - Stocks Telegraph
VCNX (Vaccinex) Short-Term Debt & Capital Lease Obligation : $0.18 Mil (As of Mar. 2024) - GuruFocus.com
VCNX (Vaccinex) Cash Flow for Lease Financing : $0.00 Mil (TTM As of Mar. 2024) - GuruFocus.com
Vaccinex (NASDAQ:VCNX) Issues Earnings Results - Defense World
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership - Markets Insider
Vaccinex reports promising Alzheimer's drug results - Investing.com
Vaccinex reports promising Alzheimer's drug results By Investing.com - Investing.com Canada
Vaccinex reports promising Alzheimer's drug results By Investing.com - Investing.com Australia
Vaccinex Provides Update on Alzheimer’s Treatment Trial - TipRanks
Vaccinex reports promising Alzheimer's drug results By Investing.com - Investing.com UK
Vaccinex Provides Update on New Findings for SIGNAL-AD - GlobeNewswire
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership - StockTitan
Albert Friedberg Acquires 3,653 Shares of Vaccinex, Inc. (NASDAQ:VCNX) Stock - Defense World
Vaccinex sees insider purchase worth over $55k by FCMI Parent Co. - Investing.com India
Vaccinex sees insider purchase worth over $55k by FCMI Parent Co. - Investing.com Canada
Around $3M Bet On This Energy Stock? Check Out These 3 Stocks Insiders Are Buying - Benzinga
Why DoorDash Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket - TradingView
Vaccinex Inc (VCNX) can make a big difference with a little luck - SETE News
Vaccinex, Inc. (NASDAQ:VCNX) Director Albert Friedberg Acquires 200,000 Shares of Stock - Defense World
Alzheimer’s drug development roundup – July 2024 - European Pharmaceutical Review
Vaccinex Inc (VCNX) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Ratios Reveal: Breaking Down Vaccinex Inc (VCNX)’s Financial Health - The Dwinnex
Vaccinex Hopes To Bring Pepinemab Forward After Alzheimer’s Results - Scrip
Vaccinex’s Phase Ib/II trial for Alzheimer’s treatment hits primary endpoint - Yahoo Finance
Vaccinex’s Phase Ib/II trial for Alzheimer’s treatment hits primary endpoint - Clinical Trials Arena
Vaccinex stock tanks 40% despite positive Alzheimer’s study update - Invezz
Vaccinex stock plunges 24% on mixed results for Alzheimer's study (NASDAQ:VCNX) - Seeking Alpha
Vaccinex Inc [VCNX] Investment Guide: What You Need to Know - Knox Daily
Vaccinex reports progress in Alzheimer's trial By Investing.com - Investing.com Nigeria
Vaccinex reports progress in Alzheimer's trial By Investing.com - Investing.com Canada
Vaccinex reports progress in Alzheimer's trial - Investing.com India
Vaccinex reports progress in Alzheimer's trial - Investing.com
Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease - GlobeNewswire
Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease - StockTitan
0.05%
4.86%
大文字化:
|
ボリューム (24 時間):